Meeting the challenge of recurrent Clostridium difficile infection

Journal of Hospital Medicine

Volumn 7, Issue SUPPL. 3, 2012, Pages

  Johnson, Stuart ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIDAXOMICIN; IMMUNOGLOBULIN; METRONIDAZOLE; PLACEBO; RIFAXIMIN; VANCOMYCIN;

ABDOMINAL CRAMP; AGED; CASE REPORT; CLOSTRIDIUM DIFFICILE INFECTION; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FEVER; FLUID RESUSCITATION; HUMAN; LEUKOCYTE COUNT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RECURRENT DISEASE; REVIEW; SACCHAROMYCES BOULARDII;

AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; FLUID THERAPY; HUMANS; HYGIENE; METRONIDAZOLE; RECURRENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; VANCOMYCIN;

EID: 84858146860     PISSN: 15535592     EISSN: 15535606     Source Type: Journal    
DOI: 10.1002/jhm.1914     Document Type: Review

References (16)

1. Kelly CP. A 76-year-old man with recurrent Clostridium difficile-associated diarrhea: review of C difficile infection. JAMA. 2009; 301(9): 954-962.
2. Norén T. Clostridium difficile and the disease it causes. Methods Mol Biol. 2010; 646: 9-35.
3. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994; 271(24): 1913-1918.
4. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002; 97(7): 1769-1775.
5. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect. 2009; 58(6): 403-410.
6. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010; 31(5): 431-455.
7. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000; 31(4): 1012-1017.
8. Riquelme AJ, Calvo MA, Guzmán AM, et al. Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin Gastroenterol. 2003; 36(1): 41-43.
9. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis. 2003; 36(5): 580-585.
10. Leung DY, Kelly CP, Boguniewicz M, et al. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr. 1991; 118(4 pt 1): 633-637.
11. Wilcox MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother. 2004; 53(5): 882-884.
12. Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis. 2007; 44(6): 846-848.
13. O'Connor JR, Galang MA, Sambol SP, et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother. 2008; 52(8): 2813-2817.
14. Crook D, Miller M, Louie T, Cornely O, Shue Y-K, Gorbach S. Efficacy and safety of fidaxomicin (FDX) vs. vancomycin (VAN) in Clostridium difficile infection (CDI) in 2 randomized controlled trials (RCT) with 1105 patients [abstract 1417]. Presented at: The 48th Annual IDSA Meeting; October 21-24, 2010; Vancouver, BC, Canada.
15. Johnson S, Crook DW, Cornely DA, High KP, Miller M, Gorbach SL. Randomized clinical trial in Clostridium difficile infection confirms superiority of fidaxomicin over vancomycin [abstract 828630]. Presented at: Digestive Disease Week 2010; May 4, 2010; New Orleans, LA.
16. Louie TJ, Miller MA, Mullane, KM, et al for the OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011; 364(5): 422-431.